Cargando…
Hormonal Contraception and Massive Pulmonary Embolism in a COVID-19 Ambulatory Patient: A Case Report
Coronavirus 19 disease (COVID-19) presents a highly variable clinical presentation and course, ranging from asymptomatic patients to rapidly progressive, fatal pneumonia. The known heterogeneous outcomes can affect both previously healthy patients and those with significant comorbidities, who develo...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700756/ https://www.ncbi.nlm.nih.gov/pubmed/34940004 http://dx.doi.org/10.3390/clinpract11040105 |
_version_ | 1784620834442182656 |
---|---|
author | Valenzuela-Vallejo, Laura Corredor-Orlandelli, David Alzate-Ricaurte, Sergio Hernández-Santamaría, Valentina Aguirre-Ruiz, Juan Felipe Peña-Peña, Adwar |
author_facet | Valenzuela-Vallejo, Laura Corredor-Orlandelli, David Alzate-Ricaurte, Sergio Hernández-Santamaría, Valentina Aguirre-Ruiz, Juan Felipe Peña-Peña, Adwar |
author_sort | Valenzuela-Vallejo, Laura |
collection | PubMed |
description | Coronavirus 19 disease (COVID-19) presents a highly variable clinical presentation and course, ranging from asymptomatic patients to rapidly progressive, fatal pneumonia. The known heterogeneous outcomes can affect both previously healthy patients and those with significant comorbidities, who develop clinical courses with possibly more multisystemic compromise. Likewise, the development of thrombotic phenomena during the acute course of the disease is associated with complications that worsen patient prognosis. We present a case report of a 45-year-old multiparous patient with a history of overweight and chronic use of oral hormonal contraception with low doses of levonorgestrel and estradiol as the only risk factors favoring the development of thrombotic events. During her outpatient COVID-19 clinical course, she developed massive pulmonary thromboembolism resulting in secondary obstructive shock, which required pharmacological thrombolysis. At discharge, hormonal contraception was considered contraindicated, and the patient was released from our institution with continued oral anticoagulant therapy. COVID-19 infection, contraceptive hormone therapy, and overweight are known risk factors for the development of thromboembolic events. The impact of their concomitance has not been studied to date. From our experience, we discuss the impact these risk factors have when present together and invite others to report similar cases. |
format | Online Article Text |
id | pubmed-8700756 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87007562021-12-24 Hormonal Contraception and Massive Pulmonary Embolism in a COVID-19 Ambulatory Patient: A Case Report Valenzuela-Vallejo, Laura Corredor-Orlandelli, David Alzate-Ricaurte, Sergio Hernández-Santamaría, Valentina Aguirre-Ruiz, Juan Felipe Peña-Peña, Adwar Clin Pract Case Report Coronavirus 19 disease (COVID-19) presents a highly variable clinical presentation and course, ranging from asymptomatic patients to rapidly progressive, fatal pneumonia. The known heterogeneous outcomes can affect both previously healthy patients and those with significant comorbidities, who develop clinical courses with possibly more multisystemic compromise. Likewise, the development of thrombotic phenomena during the acute course of the disease is associated with complications that worsen patient prognosis. We present a case report of a 45-year-old multiparous patient with a history of overweight and chronic use of oral hormonal contraception with low doses of levonorgestrel and estradiol as the only risk factors favoring the development of thrombotic events. During her outpatient COVID-19 clinical course, she developed massive pulmonary thromboembolism resulting in secondary obstructive shock, which required pharmacological thrombolysis. At discharge, hormonal contraception was considered contraindicated, and the patient was released from our institution with continued oral anticoagulant therapy. COVID-19 infection, contraceptive hormone therapy, and overweight are known risk factors for the development of thromboembolic events. The impact of their concomitance has not been studied to date. From our experience, we discuss the impact these risk factors have when present together and invite others to report similar cases. MDPI 2021-11-26 /pmc/articles/PMC8700756/ /pubmed/34940004 http://dx.doi.org/10.3390/clinpract11040105 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Valenzuela-Vallejo, Laura Corredor-Orlandelli, David Alzate-Ricaurte, Sergio Hernández-Santamaría, Valentina Aguirre-Ruiz, Juan Felipe Peña-Peña, Adwar Hormonal Contraception and Massive Pulmonary Embolism in a COVID-19 Ambulatory Patient: A Case Report |
title | Hormonal Contraception and Massive Pulmonary Embolism in a COVID-19 Ambulatory Patient: A Case Report |
title_full | Hormonal Contraception and Massive Pulmonary Embolism in a COVID-19 Ambulatory Patient: A Case Report |
title_fullStr | Hormonal Contraception and Massive Pulmonary Embolism in a COVID-19 Ambulatory Patient: A Case Report |
title_full_unstemmed | Hormonal Contraception and Massive Pulmonary Embolism in a COVID-19 Ambulatory Patient: A Case Report |
title_short | Hormonal Contraception and Massive Pulmonary Embolism in a COVID-19 Ambulatory Patient: A Case Report |
title_sort | hormonal contraception and massive pulmonary embolism in a covid-19 ambulatory patient: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700756/ https://www.ncbi.nlm.nih.gov/pubmed/34940004 http://dx.doi.org/10.3390/clinpract11040105 |
work_keys_str_mv | AT valenzuelavallejolaura hormonalcontraceptionandmassivepulmonaryembolisminacovid19ambulatorypatientacasereport AT corredororlandellidavid hormonalcontraceptionandmassivepulmonaryembolisminacovid19ambulatorypatientacasereport AT alzatericaurtesergio hormonalcontraceptionandmassivepulmonaryembolisminacovid19ambulatorypatientacasereport AT hernandezsantamariavalentina hormonalcontraceptionandmassivepulmonaryembolisminacovid19ambulatorypatientacasereport AT aguirreruizjuanfelipe hormonalcontraceptionandmassivepulmonaryembolisminacovid19ambulatorypatientacasereport AT penapenaadwar hormonalcontraceptionandmassivepulmonaryembolisminacovid19ambulatorypatientacasereport |